The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
Authors:
- Lauro MeneghelLMLauro Meneghel
- Amelia RuffattiARAmelia Ruffatti
- Sabrina GavassoSGSabrina Gavasso
- Marta TonelloMTMarta Tonello
- Elena MattiaEMElena Mattia
- Luca SpieziaLSLuca Spiezia
- Elena CampelloECElena Campello
- Ariela HoxhaAHAriela Hoxha
- Marny FedrigoMFMarny Fedrigo
- Leonardo PunziLPLeonardo Punzi
- Paolo SimioniPSPaolo Simioni
- 1 January 2015
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 53 (7) , 1083-1089
Abstract
Fully automated chemiluminescence immunoassays (CLIAs) are emerging technologies for the detection of antiSera were collected from 104 patients with primary APS, 88 seronegative subjects who met the clinical but not the laboratory criteria for APS, and 150 control subjects. IgG/IgM aCL and IgG/IgM anti-β2GPI antibodies were determined in the sera using a CLIA (HemosIL AcuStarCLIA had a significantly lower comparative sensitivity for IgM aCL and IgG/IgM IgG anti-β2GPI antibodies; its comparative specificity was higher with respect to ELISA for IgM aCL and IgM anti-β2GPI antibodies. The two techniques showed a high, significant agreement (p<0.001) and a significant titer correlation (p<0.001). CLIA also detected IgG/IgM aCL and IgG anti-β2GPI antibodies in the seronegative patients. There was a significantly higher prevalence of IgG aCL and IgG anti-β2GPI antibodies (p<0.001 and p=0.01, respectively) in those patients with respect to that in the control population.Despite a lower comparative sensitivity, CLIA showed a higher comparative specificity for some aPL and a good level of agreement and correlation with a homemade ELISA. CLIA also detected some aCL and anti-β2GPI antibodies in the seronegative patients not usually identified by homemade ELISA.Keywords
This publication has 17 references indexed in Scilit:
- Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti‐beta2‐glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndromeInternational Journal of Laboratory Hematology, 2012
- Influence of different IgG anticardiolipin antibody cut‐off values on antiphospholipid syndrome classificationJournal of Thrombosis and Haemostasis, 2008
- Technical Aspects in Laboratory Testing for Antiphospholipid Antibodies: Is Standardization an Impossible Dream?Seminars in Thrombosis and Hemostasis, 2008
- A Quarter of a Century in Anticardiolipin Antibody Testing and Attempted Standardization Has Led Us to Here, which Is?Seminars in Thrombosis and Hemostasis, 2008
- Are the Current Attempts at Standardization of Antiphospholipid Antibodies Still Useful? Emerging Technologies Signal a Shift in DirectionSeminars in Thrombosis and Hemostasis, 2008
- Invitation to a debate on the serological criteria that define the antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2008
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assaysPathology, 2004
- Seronegative antiphospholipid syndromeAnnals of the Rheumatic Diseases, 2003
- A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodiesArthritis & Rheumatism, 1999